Bexobrutideg
Bexobrutideg is an investigational new drug that is being evaluated by Nurix Therapeutics for the treatment of elapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia and Waldenström macroglobulinemia. It is an orally bioavailable, brain-penetrant Bruton's tyrosine kinase degrader.